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Summary.-The hypoxic cell sensitizer Misonidazole (Ro-07-0582) induces oncogenic
transformations in the C3H/1OTI mouse embryo cell line cultured in vitro. A drug
concentration of 04 mM applied to aerated cells for 3 or 6 days results in a trans-
formation rate comparable to that observed following an X-ray dose of 1 Gray. A
higher drug concentration of 6 0 mM is equivalent to 4 Gy. The combination of
Misonidazole and X-rays produces a significant increase in the frequency of trans-
formation over either drug or radiation alone, but the data are equivocal on the
question of additivity vs synergism.
CELLS DEFICIENT in oxygen are relative-
ly resistant to killing by X- or y-rays, and
it has frequently been suggested that this
fact limits the radiocurability of some
human tumours by conventional radio-
therapy. In recent years, a variety of
compounds have been studied which selec-
tively sensitize hypoxic mammalian cells
to X- or y-rays. The most promising ofthe
new drugs is the 2-nitroimidazole, Miso-
nidazole (Ro-07-0582), which satisfies
many of the criteria essential for a clinic-
ally useful sensitizer (Adams, 1973; Adams
and Dewey, 1963; Asquith et al., 1974).
Following extensive investigations with
radiobiological test systems in vitro and
in vivo, Misonidazole (MIS) is currently
undergoing clinical trials in humans
(Brown, 1975; Chapman et al., 1973;
Denekamp and Harris, 1975; Foster et al.,
1976; Gray et al., 1976; Hall and Roizin-
Towle, 1975).
From the numerous reports that have
appeared in the literature, MIS appears to
act selectively on hypoxic cells as both a
radiosensitizer and cytotoxic agent; it has
no cell-killing effect on aerated cells, ex-
cept at high concentrations and/or pro-
longed contact times. However, it is
obviously desirable to investigate the
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possibility that MIS could produce onco-
genic transformations in aerated cells, and
this is now possible using sensitive in vitro
methods that have been developed in
recent years. This need was made more
urgent by the reports of Connor et al.
(1977), Speck et al. (1976) and Voogd et al.
(1974), who established that the family of
5-nitroimidazole derivatives have muta-
genic potential in two strains of bacteria,
K. pneumoniae and S. typhimuritm. With
the increased probability of long-term
patient survival after the combination of
radiation and the new sensitizers, it is
important to consider possible late effects.
Specifically, the carcinogenicity of MIS
must be determined in order to allow an
assessment of the risks and benefits in-
volved in using the nitroimidazoles as
adjuncts to radiotherapy.
MATERIALS AND METHODS
(a) Culture of the cells.-The C3H/1OT1 cell
line, developed in the laboratory of Charles
Heidelberger, has been reported to be highly
sensitive to post-confluence inhibition of cell
division (Reznikoff et al., 1973a). These cells
are fibroblasts from the ventral prostate of
C3H mouse embryos. Cells used for experi-
ments were between Passages 12 and 16,R. C. MILLER AND E. J. HALL
because of the report that cells of later pass-
ages have an incidence of spontaneous trans-
formation. Cells were grown in Eagle's basal
medium (BME), supplemented with 10%
heat-inactivated foetal calf serum. Penicillin
(50 u/ml) and streptomycin (50 jug/ml) were
added to control bacterial contamination.
Cells were seeded into 100 mm Falcon plastic
Petri dishes 24 h before the treatment with
MIS or X-rays or both; the number of cells
plated was such that between 350 and 450
viable cells per dish survived the subsequent
treatment. A range ofdrug concentration was
used, and the cells were treated for 3 days or
6 days. At the termination of the drug ex-
posure, medium containing MIS was replaced
with fresh drug-free complete medium. Sub-
sequently, medium was changed weekly for
6 weeks until untransformed cells had formed
a confluent layer in the dish, and transformed
foci were large enough to be readily visible.
(b) Transformation evaluation.-Trans-
formed foci were evaluated using the morpho-
logical criteria described by Reznikoff et al.
(1973a, b). Three types of morphologically
differing foci can be identified. Type 1 foci
appear as groups oftightly packed cells. Type
2 foci have extensive piling up of cells and
moderate criss-crossing of the cells at the
border of the clone. Type 3 foci are very
densely piled up stellate cells withpronounced
criss-crossing and swirling of cells at the edge
of the clone (Fig. 1). Only Type 3 foci were
scored as transformants since Reznikoff et al.
(1973b) reported that foci of this type pro-
duced tumours in 85% of the C3H recipient
mice. No spontaneous invitro transformations
were observed in untreated controls in any
of the experiments reported, indicating that
the spontaneous transformation frequency
was extremely low.
(c) Methods of irradiation.-The source of
Fia. 1.-Photograph of a Type III transformed focus. Note the dense piling of cells with criss-crossing at
the border of the colony ( x 15).
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X-rays was a 300 kV conistant-potential
generator, operated at 12 mA, with added
filtration of 0 2 mm of copper. Cells attached
to Petri dishes w%ere irradiated at a treatment
distance of 69 cm. Dosimetry was based on
ionization measurements with a Victoreen
R-meter; at the position occupied by the
cells the dose rate w%vas computed as 1 05
Gy/min.
RESULTS
Fig. 2 shows growth curves for C3H/
1OT2 cells cultured in the presence of
various concentrations of MIS. Cells in
control dishes grow until there are 3 x
b .%
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Fie. 2. Growth curve of C3H/lOTt cells in
the presence of various concentrations of
AIIS for up to 7 days.
106 cells per Petri dish (100 mm diameter),
by which time the cells are confluent and
growth ceases because the cells are contact-
inhibited. Concentrations of MIS up to
about 2 mm cause a progressive slowving of
growth, but 5 mm completely inhibits
growth. However, in this case, if the drug
is removed and fresh growth medium
added, normal growth will resume after a
lag of about a day. The effectiveness of
MIS in killing cells is shown in Fig. 3,
where the fraction of cells surviving is
plotted against the drug concentration for
a 3- or 6-day exposure. Inhibition of the
growth of V79 cells under aerated condi-
tions while exposed to high concentrations
of MIS was previously reported by Strat-
ford and Adams (1977). While it is usually
c
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FIG. 3.--Survival curves ofaeratedC3H/1OTI
cells exposed to various concentrations of
MIS for 3 days (0) or 6 days (0-).
claimed that the nitroimidazoles are
specifically cytotoxic to hypoxic cells, both
cell killing and growth inhibition occur in
aerated cells at high drug concentration,
as is evident from Figs. 2 and 3.
A series of experiments was performed
in which concentrations ofMIS from 0.4 to
8 mm were added to cells for either 3 or
6 days, and the rate of transformation
subsequently assayed. The data are sum-
marized in Table I and plotted in Fig. 4b,
where the number of transformants per
surviving cell is plotted as a function of
drug concentration. A total of 27 separate
experiments were performed, most of
them involving the clinically relevant drug
concentrations in the range 0 4 to 2 mm.
The lowest concentration used (0.4 mM)
resulted in a significant transformation
rate. In experiments performed at this
laboratory during the past year a total of
over one million clones have been counted
on the control dishes (without drug) with-
out the appearance of a single transformed
clone. This means that the spontaneous
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TABLE I.-Frequency oftransformation after addition ofMIS (0.4-0Q8 mM)for 3 or 6 days
Conc.
Misonidazole
(mM)
0 4
1.0
2 0
5 0
6 0
8 0
0 5
1.0
2 0
Exposure
time
(days)
3
3
3
3
3
3
6
6
6
(combined controls)
* Plating efficiency.
No. cells
per dish
415
447
385
324
382
490
362
394
483
416
505
455
395
284
540
295
350
455
325
499
319
463
401
194
368
525
254
435
No. of
dishes
29
76
60
108
55
65
104
95
61
48
180
32
60
77
43
49
40
44
65
132
60
51
65
37
76
60
70
475
Surviving
fraction
0 93
0 90
0.95
0-91
0 88
0 65
0 80
0 85
0 89
0 40
0 36
0 30
0 43
0-01
0 02
001
0-0011
0 90
0 93
0 85
0 75
0 65
0 72
0 26
0 30
0 34
0 25
0-18*
No. of
transformed
clones
Total surviving
cells
3/1 20x 104
9/3-40x 104
8/2 31 x 104
8/3 50x104
6/2.10x 104
11/3-20X 104
8/3*77x 104
11/3-74X 104
10/2 93x104
6/2 00X104
22/9-10x 104
7/1 46x 104
10/2.37x 104
30/2.20x104
21/2.32x 104
14/1*45x 104
14/1 40x 104
6/2 00X104
6/2. 11 x 104
20/6 59x 104
6/1-91 x 104
5/2*36x 104
20/2 61 x 104
4/0-72x 104
12/2-80x 104
15/3-15x 104
8/1 78 X 104
0/2-07 x 105
Frequency of
transformation
(X 10-4±s.e.)
2 71±0 26
2 95±0 24
3 61±0 55
11 300-23
9 66
10*00
2 96±0 05
2 95±0 44
4 50±0 46
0
transformation rate is less than 10-6. The
rate of transformation clearly increases
with drug concentration. On the other
hand, the period for which the drug is in
contact with the cells (3 or 6 days) appears
to have little influence on the number of
cells transformed. It is relevant and in-
teresting to compare the potential car-
cinogenicity of MIS with other known
carcinogens, such as X-rays. Fig. 4a shows
the relationship between transformation
and X-ray dose; the number of transfor-
mants per surviving cell increases with
dose, but approaches a plateau at a fre-
quency of about 2 x 10-3 for doses over
6 Gy. By comparing Panels (a) and (b) of
Fig. 4 it is possible to calculate the drug
concentrations that are equivalent to
various doses of X-rays in their ability to
induce transformation. This "equivalence"
is summarized in Fig. 5, where the dose of
radiation is plotted against the concentra-
tion of MIS which results in the same
frequency of transformation.
The results of experiments in which
MIS was combined with X-rays are sum-
marized in Table II and plotted in Fig. 6.
The combination of drug and radiation
resulted in a significant increase in the
frequency of transformations compared
with X-rays or drug alone. The drug treat-
ment was a 3-day exposure to a concen-
tration of 1 mm, beginning 24 h before
irradiation and continuing for 48 h after-
wards. Three doses of X-rays were used,
1, 2 and 4 Gy.
DISCUSSION
Misonidazole promises to be a valuable
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FIG. 4.-The proportion ofC3H/lOTJ cells transformed (a) as a function of X-ray dose. (b) as a function of
concentration of MIS for 3 days (0) or 6 days (0).
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FIG. 5.-A comparison of the dose of X-rays (Gy) and the concentration of MIS (for 3 days) required to
produce an equal incidence of transformation in C3H/lOTJ cells.
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TABLE II.-Frequency of transfornation (transformnants per 104 surviving cells)
Treatment
1 mm MIS and/or 1 Gy X-rays
1 m-II MIS and/or 2 Gy X-rays
1 mat MIS and/or 4 Gy X-rays
AIIS
(:3-day exposture)
2-12
2 -94
2 53X0 41
3 41
2 -94
3-184-0 24
2-12
2-94
X-ray
alone
2 35
1-90
2- 134-0-23
3-87
2 -56
3-22+0-23
9 -48
7 -36
Combination
MIS+X-rays*
6-21
4-53
(0 33)*
(0 36)
5-374i0-84 (0-35)
15-0 (0-15)
8-51 (0-25)
11-8+3-2 (0-20)
20-0 (0-16)
12-3 (0-19)
2-53+0-41 8-42+1-06 16-2-L3-9 (0-18)
* In parentheses, sturviving fraction.
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FIG. 6. The proportion of C3H/1OTI cells
transformed by various doses of X-rays,
with and without MIS (1 mAi) for 3 days.
addition to the armamentarium of the
radiotherapist because itsensitizes hypoxic
cells which are otherwise relatively re-
sistant to X-rays and may limit the radio-
curability of some human tumours
(Asquith et al., 1974; Denekamp and
Harris, 1975; Thomlinson and Gray,
1955). MIS may also find a place in multi-
drug chemotherapy regimens, because it,
is also cytotoxic towards hypoxic cells
(Hall et al., 1977, Hall and Roizin-Towle,
1975; Stratford and Adams, 1977).
These undoubted benefits must be
weighed against the possibility that the
nitroimidazoles are potent carcinogens.
When MIS is used clinically as a sensitizer
in conjunction with radiotherapy, serum
levels in the range 0 5 to 1 mm can be
achieved. The maximum serum concen-
tration occurs 3 to 4 h after oral admini-
strations of the drug, and subsequently
decays exponentially with a half-life of
,-1,2 h. Based on Fig. 5, this drug treat-
ment carried with it a carcinogenic poten-
tial equal to an X-ray dose of about 1 Gy.
It is pertinent to note that when radiation
is used as a therapeutic modality, the high
dose is confined to the tumour, its immedi-
ate surroundings and the necessary transit
normal tissues. By contrast, when MIS is
used clinicallv it comes into contact with
virtually all the normal tissues ofthe body.
The experiments combining MIS and
X-rays showed that the combination pro-
duces a significant increase in the fre-
quency of transformations compared with
either the drug or the radiation alone. It
wrould clearly be of interest to know
whether the interaction between the two
agents is additive or synergistic. The drug
treatment alone (1 mm for 3 days) resulted
in a transformation frequency of about
2*5X 10-4. A dose of 1 Gy alone produced
a transformation frequency of about 2 1 x
10-4. The combination of 1 Gy plus drug
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resulted in a frequency ofabout 5-2 x 10-4,
which is not significantly different from
the sum of the individual contributions of
the two modalities (2.5+2.1=z46) which
would suggest additivity between radia-
tion and drug. However, when 2 Gy of
X-rays was combined with the drug treat-
ment, the transformation frequency pro-
duced (13 x 10-3) was significantly greater
than the sum of the frequencies produced
by drug and radiation alone (2-5+3*2=
5.7 X 10-4) which suggests synergism in the
action of drug and radiation. It is difficult
to draw any conclusions from the highest
radiation dose used, because the trans-
formation frequency produced by 4 Gy+
drug approaches the plateau of about 2 x
10-3, which appears never to be exceeded
by either radiation or drug treatments.
The present data, therefore, clearly show
that combining radiation and MIS results
in more transformations than either agent
alone, but is equivocal on the question of
additivity vs synergism.
These studies with an in vitro transfor-
mation system have shown that the new
generation of hypoxic cell sensitizers have
as great a potential as radiation for pro-
ducing oncogenic transformation. They
highlight the need for further investiga-
tions with more complex animal model
systems. When new drugs such as MIS
have passed their early clinical tests and
are used in younger patients with less
advanced tumours, who therefore have a
longer life expectancy, the possibility of
inducing a second neoplasm while treating
the first can no longer be ignored.
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